Another milestone reached to develop highly accurate Covid-19 test
Wetherby-based business Avacta Group has confirmed another key step on its path towards bringing to market its test for detecting COVID-19.
The company says the Declaration of Conformity for CE mark of its AffiDX® SARS-CoV-2 antigen rapid test for professional use has been submitted to the Medicines and Healthcare products Regulatory Agency (MHRA) through its partner – Mologic Limited.
Avacta has developed the SARS-CoV-2 antigen lateral flow test using its proprietary Affimer® platform.
It recently announced data from a clinical study on 98 positive COVID-19 samples that demonstrate excellent performance in identifying the SARS-CoV-2 virus across a broad range of viral loads.
The Group expects to receive confirmation of the registration of the AffiDX® in-vitro diagnostic device in the coming days, which will allow it to immediately place the test on the market.
Dr Alastair Smith, chief executive of Avacta Group, said: “I am absolutely delighted to have reached this significant milestone for the Diagnostics Division and Avacta Group.
“I am very proud of the quality and performance of Avacta’s AffiDX® antigen test.
“As part of the recent clinical study the same clinical samples were tested with two leading, commercially available lateral flow antigen tests, and the data show that the AffiDX® test had better clinical sensitivity across the range of Ct values tested and, in particular, at lower viral loads.
“We are very excited by the potential of this high quality SARS-CoV-2 rapid antigen test and the interest that we have received for it from potential commercial partners, distributors and end users.
“We are looking forward to receiving confirmation of the registration from MHRA in the coming days, allowing the Group to immediately place the test on the market.“